Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odanacatib - Merck & Co

Next Previous
Search
Drug Profile

Odanacatib - Merck & Co

Alternative Names: MK-0822; MK-822

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celera Group
  • Developer Banyu; Merck & Co
  • Class Amides; Biphenyl compounds; Cyclopropanes; Nitriles; Osteoporosis therapies; Small molecules; Sulfones
  • Mechanism of Action Bone resorption factor inhibitors; Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone metastases; Corticosteroid-induced osteoporosis; Male osteoporosis; Osteoarthritis; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 26 Sep 2016 Merck Sharp & Dohme terminates a phase I trial in Corticosteroid-induced osteoporosis (In adolescents, Prevention, In adults) in USA, United Kingdom, Italy and Finland (NCT01630616, EudraCT2012-003414-14)
  • 16 Sep 2016 Efficacy and adverse events data from an extension study of the phase III LOFT trial in Osteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research
  • 02 Sep 2016 Discontinued - Phase-I for Corticosteroid-induced osteoporosis (In adolescents, Prevention, In adults) in United Kingdom, Italy, Finland, South Korea, USA (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top